Credit Suisse Ag Verve Therapeutics, Inc. Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
A detailed history of Credit Suisse Ag transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 65,742 shares of VERV stock, worth $320,820. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65,742
Previous 62,853
4.6%
Holding current value
$320,820
Previous $876,000
0.34%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding VERV
# of Institutions
170Shares Held
78.3MCall Options Held
125KPut Options Held
185K-
Alphabet Inc. Mountain View, CA12.3MShares$60.3 Million7.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.33MShares$30.9 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.04MShares$29.5 Million0.57% of portfolio
-
Black Rock Inc. New York, NY5.37MShares$26.2 Million0.0% of portfolio
-
State Street Corp Boston, MA5.1MShares$24.9 Million0.0% of portfolio
About Verve Therapeutics, Inc.
- Ticker VERV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,942,300
- Market Cap $293M
- Description
- Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...